OptiBiotix Health (LON:OPTI) Hits New 52-Week Low – Should You Sell?

Shares of OptiBiotix Health Plc (LON:OPTI) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as GBX 7.16 and last traded at GBX 7.38, with a volume of 278564 shares changing hands. The stock had previously closed at GBX 7.72.

OptiBiotix Health Price Performance

The company has a market capitalization of £6.83 million, a P/E ratio of -220.33 and a beta of 1.71. The firm has a fifty day moving average price of GBX 8.43 and a 200-day moving average price of GBX 10.42.

OptiBiotix Health (LON:OPTI) last posted its quarterly earnings data on Tuesday, September 16th. The company reported GBX (1.15) earnings per share for the quarter. OptiBiotix Health had a negative return on equity of 36.76% and a negative net margin of 524.43%.

Insider Transactions at OptiBiotix Health

In related news, insider David Blain purchased 84,053 shares of OptiBiotix Health stock in a transaction that occurred on Wednesday, October 1st. The stock was bought at an average price of GBX 1,175 per share, for a total transaction of £987,622.75. Also, insider Stephen O’Hara acquired 95,238 shares of the firm’s stock in a transaction that occurred on Tuesday, September 23rd. The shares were bought at an average price of GBX 11 per share, with a total value of £10,476.18. Insiders purchased a total of 229,291 shares of company stock worth $100,309,893 over the last three months. 26.82% of the stock is owned by insiders.

OptiBiotix Health Company Profile

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome – the collective genome of the microbes in the body – in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements.